palbociclib (Ibrance)
Jump to navigation
Jump to search
Indications
- metastatic breast cancer* in postmenopausal women
* doubles time to progression or death[1]
* intended for postmenopausal women with estrogen receptor- positive, HER2-negative metastatic breast cancer who have not received endocrine-based therapy
* also indicated for recurrent metastatic estrogen receptor-positive, HER2-negative breast cancer after prior aromatase inhibitor therapy[3]
* used in combination with letrozole
Adverse effects
- bone marrow suppression[2]
- nausea, vomiting, diarrhea
- stomatitis
- alopecia
- fatigue, asthenia, anorexia
- peripheral neuropathy
- upper respiratory tract infection
- epistaxis[2]
Mechanism of action
- cyclin-dependent kinase inhibitor (CDK4/CDK6 inhibitor)[1]
Notes
- FDA-approved (Feb 2015)
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 Finn RS et al Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). American Association for Cancer Research. 2014 Annual Meeting. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=113bcbb9-585d-4939-b5de-99e11e302ef2&cKey=54090e4a-2f25-4594-83b3-37e21e120e6b&mKey=6ffe1446-a164-476a-92e7-c26446874d93
- ↑ 2.0 2.1 2.2 FDA News Release. February 3, 2015 FDA approves Ibrance for postmenopausal women with advanced breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ Turner NC, Ro J, Andre F et al for the PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26030518 Free Article